Last updated: September 16, 2026
Trandolapril/verapamil hydrochloride is an established fixed-dose combination for hypertension marketed in the United States as Tarka. Its commercial opportunity is primarily generic and lifecycle-oriented rather than based on new chemical entity protection. The main technical challenge is coordinating immediate-release delivery of trandolapril with sustained-release delivery of verapamil hydrochloride in a stable, bioequivalent oral dosage form.
The strongest opportunities are lower-cost generic manufacture, improved modified-release platforms, lower tablet burden, differentiated strengths, and geographic expansion in markets where fixed-dose renin-angiotensin system and calcium-channel blocker combinations remain underpenetrated.
What is trandolapril and verapamil hydrochloride?
Trandolapril is an angiotensin-converting enzyme inhibitor. Verapamil hydrochloride is a non-dihydropyridine calcium-channel blocker. The combination lowers blood pressure through complementary mechanisms and is indicated for hypertension in patients who require combination therapy.[1]
The original product, Tarka, uses extended-release verapamil hydrochloride with immediate-release trandolapril. FDA-approved strengths include:
| Product strength |
Trandolapril |
Verapamil hydrochloride |
Release profile |
| Tarka 1/240 |
1 mg |
240 mg |
Immediate-release trandolapril; extended-release verapamil |
| Tarka 2/180 |
2 mg |
180 mg |
Immediate-release trandolapril; extended-release verapamil |
| Tarka 2/240 |
2 mg |
240 mg |
Immediate-release trandolapril; extended-release verapamil |
| Tarka 4/240 |
4 mg |
240 mg |
Immediate-release trandolapril; extended-release verapamil |
The product is a tablet rather than a capsule or multiparticulate system. Its development logic is to preserve rapid exposure to trandolapril while controlling verapamil release over the dosing interval.
What excipients are used in trandolapril/verapamil hydrochloride tablets?
Public product labeling identifies conventional tablet excipients associated with the Tarka formulation, including lactose monohydrate, microcrystalline cellulose, povidone, crospovidone, colloidal silicon dioxide, magnesium stearate and coating materials.[1] Exact qualitative and quantitative composition can vary by strength, manufacturer and jurisdiction.
A commercial formulation must address four excipient functions:
- Immediate-release delivery of trandolapril.
- Sustained release of verapamil hydrochloride.
- Chemical and physical stability of both active ingredients.
- Mechanical performance during compression, coating, packaging and storage.
Excipient function by formulation component
| Formulation need |
Candidate excipient classes |
Primary technical role |
| Tablet filler |
Lactose, microcrystalline cellulose, mannitol, dibasic calcium phosphate |
Tablet mass, compressibility and content uniformity |
| Binder |
Povidone, copovidone, hydroxypropyl cellulose |
Granule strength and tablet integrity |
| Disintegrant |
Crospovidone, croscarmellose sodium, sodium starch glycolate |
Rapid breakup of the immediate-release component |
| Lubricant |
Magnesium stearate, sodium stearyl fumarate |
Ejection and tooling protection |
| Glidant |
Colloidal silicon dioxide |
Powder flow and blend uniformity |
| Release controller |
Ethylcellulose, hypromellose, methacrylate polymers, lipid matrices |
Sustained verapamil release |
| Film coat |
Hypromellose, polyethylene glycol, titanium dioxide, iron oxides |
Protection, identification and swallowability |
| Moisture-control system |
High-barrier blister, desiccant bottle, moisture-resistant coat |
Stability protection |
The most important design issue is that a conventional disintegrant system can accelerate release of the verapamil fraction if the sustained-release matrix is not physically separated or adequately controlled.
How should the excipient strategy be designed?
The preferred strategy is a dual-phase tablet in which trandolapril is incorporated into an immediate-release matrix and verapamil hydrochloride is incorporated into a separate sustained-release matrix. A bilayer tablet, coated subunit or compressed-in-compression design can reduce interaction between the two release systems.
Immediate-release trandolapril phase
Trandolapril is used at a low dose relative to verapamil. The immediate-release phase requires strong content-uniformity control because small assay deviations can materially affect dose accuracy.
Microcrystalline cellulose and lactose are practical fillers. Povidone or copovidone can improve granule strength. Crospovidone is suitable where rapid disintegration is required. Magnesium stearate should be controlled because excessive lubrication can slow wetting and reduce dissolution.
A direct-compression approach can reduce manufacturing steps, but wet granulation may provide better content uniformity when trandolapril is present at a low loading. The selection depends on powder-flow properties, blend segregation and the target process capability.
Sustained-release verapamil phase
Verapamil hydrochloride is the dominant mass component. The formulation can use a hydrophilic matrix based on hypromellose or a hydrophobic matrix based on ethylcellulose and related polymers.
A hydrophilic matrix is generally easier to scale and adjust. Release depends on polymer grade, polymer concentration, tablet porosity, compression force and dissolution medium. A hydrophobic matrix can offer greater resistance to rapid release but may introduce more complex process and dissolution behavior.
The target is a reproducible release profile that avoids dose dumping. Verapamil release must be assessed under elevated agitation, alcohol exposure where relevant, pH variation and fed/fasted conditions. The FDA modified-release guidance and product-specific bioequivalence expectations should guide study design.[2]
What formulation patents protect trandolapril and verapamil hydrochloride?
The original composition-of-matter patents for trandolapril and verapamil hydrochloride are expired or near-certainly expired in the United States. The main remaining intellectual-property questions concern formulation, release profile, manufacturing process and method of use.
Potential claim categories include:
| Claim category |
Commercial relevance |
Likely status |
| Trandolapril compound claims |
Protect the active ingredient |
Expired |
| Verapamil hydrochloride compound claims |
Protect the active ingredient |
Expired |
| Fixed-dose combination claims |
Protect the combination |
Expired or commercially weak |
| Extended-release verapamil formulation |
Protect release control |
Historical or expired in major markets |
| Bilayer or multiparticulate dosage form |
May support differentiated generic design |
Dependent on jurisdiction and filing date |
| Manufacturing process |
Can restrict a specific process, not necessarily the product |
Requires claim-by-claim review |
| Method-of-use claims |
May cover treatment of hypertension or selected populations |
Generally weak where broad treatment use is known |
| Stability or packaging claims |
Can protect a narrow product configuration |
Potentially relevant to lifecycle products |
A definitive patent opinion requires a jurisdiction-specific review of national registers, Orange Book listings, prosecution histories, terminal disclaimers, continuations and litigation records. Public FDA records should be checked against the latest Orange Book and Drugs@FDA entries before launch planning.[3,4]
When does trandolapril/verapamil lose exclusivity?
The principal U.S. market exclusivity for the combination has expired. Tarka was approved in the 1990s, and the product is no longer protected by new chemical entity exclusivity. Any commercial barrier is therefore more likely to arise from regulatory requirements, manufacturing complexity, market size or residual formulation patents than from basic active-ingredient exclusivity.
| Exclusivity category |
Assessment |
| New chemical entity exclusivity |
Expired |
| Orphan-drug exclusivity |
Not applicable |
| Pediatric exclusivity |
No material current barrier identified |
| Basic compound patents |
Expired |
| Fixed-dose combination patents |
Historically important, but generally expired |
| Formulation patents |
Must be verified by jurisdiction and claim scope |
| Regulatory exclusivity for a new generic |
Not applicable unless a qualifying first-filer right exists |
| Biosimilar exclusivity |
Not applicable; this is a small-molecule product |
There is no biosimilar pathway for this product. Applicants use the abbreviated new drug application pathway for an equivalent immediate-release/extended-release combination, subject to FDA requirements.
What is the Orange Book status of Tarka?
Tarka is an FDA-approved small-molecule combination product. Orange Book review should focus on:
- Active ingredient listings for trandolapril and verapamil hydrochloride.
- Dosage-form and strength-specific reference product designations.
- Any listed patents and their expiration dates.
- Whether the relevant reference product is currently marketed.
- Whether FDA identifies a reference listed drug for each strength.
- Any therapeutic-equivalence codes for approved generic products.
Because Orange Book listings can change and discontinued products may affect reference-product strategy, a launch team should use the current FDA Orange Book rather than relying on historical patent summaries.[3]
How many patents cover trandolapril and verapamil hydrochloride?
The number depends on the jurisdiction, search date and definition of “cover.” A simple count of documents can overstate the commercial estate because one invention may have a U.S. patent, continuations, foreign counterparts and later expirations.
The relevant commercial estate is likely to be narrow for the original product and concentrated in:
- Historical combination patents.
- Extended-release verapamil technology.
- Process patents.
- Formulation and stability claims.
- Foreign national rights with different expiration dates.
The practical strength of the estate is low for blocking a conventional generic containing the same active ingredients, provided that the generic does not practice an unexpired formulation claim.
What generic entry risks exist?
Generic entry risk is high because the active ingredients are established and the product is a small molecule. The main risks are technical rather than compound-patent risks.
Regulatory risks
The applicant must demonstrate pharmaceutical equivalence and bioequivalence for the combination product. Modified-release verapamil creates the principal development burden. Dissolution must be discriminatory enough to detect formulation differences, while in vivo studies must show comparable exposure over the dosing interval.
Relevant risk areas include:
- Failure to match the reference release profile.
- Food-effect differences.
- Dose dumping under altered pH or high agitation.
- Inadequate control of trandolapril content uniformity.
- Degradation during accelerated stability testing.
- Mismatch between the proposed product and the reference product’s marketed configuration.
Manufacturing risks
The product has a high verapamil-to-trandolapril dose ratio. This increases the risk of blend segregation and low-dose content-uniformity failure. A segregated bilayer or granulated trandolapril phase can reduce that risk.
Other barriers include:
- Scale-up of polymer hydration and matrix formation.
- Tablet weight variation.
- Compression-force sensitivity.
- Coating defects.
- Lubricant overmixing.
- Moisture-related degradation.
- Equipment requirements for multilayer compression.
Which companies are challenging the Tarka market?
The competitive field consists primarily of generic manufacturers with capabilities in extended-release tablets and combination products. Likely commercial participants include large U.S. generic suppliers, vertically integrated manufacturers and regional companies with hypertension portfolios.
The most credible competitors are those with:
- Existing FDA-approved verapamil extended-release products.
- Experience with ANDA development for combination tablets.
- Controlled-release dissolution laboratories.
- Multilayer or modified-release tablet manufacturing.
- Established distribution through wholesalers and pharmacy benefit channels.
The commercial market is likely price-sensitive. A new entrant may need manufacturing-cost advantages or supply reliability rather than clinical differentiation.
What commercial opportunities exist for excipient suppliers?
Excipient suppliers can capture value in four areas.
Modified-release polymers
Hypromellose, ethylcellulose and methacrylate-based systems can support differentiated dissolution profiles. Suppliers with regulatory documentation, global compendial support and consistent viscosity grades have an advantage.
Direct-compression excipients
Co-processed microcrystalline cellulose systems, spray-dried lactose and multifunctional fillers can improve flow, compressibility and content uniformity. These products can reduce granulation requirements and shorten manufacturing cycles.
Low-moisture formulations
Moisture-controlled excipient systems and protective coatings can improve stability. This is relevant where trandolapril or formulation intermediates show sensitivity to hydrolysis or oxidation.
Taste, swallowability and tablet-size reduction
Verapamil creates a large tablet mass. High-functionality excipients and higher tablet tensile strength can reduce tablet size while preserving dissolution. Film coatings can improve swallowability and product identification.
How does trandolapril/verapamil compare with competing antihypertensive combinations?
| Combination |
Main technical profile |
Commercial implication |
| Trandolapril/verapamil |
ACE inhibitor plus non-dihydropyridine calcium-channel blocker; modified-release tablet |
Niche combination with formulation complexity |
| ACE inhibitor/amlodipine |
ACE inhibitor plus dihydropyridine calcium-channel blocker |
Broader hypertension use and stronger generic competition |
| ARB/amlodipine |
Angiotensin receptor blocker plus dihydropyridine calcium-channel blocker |
Large class with extensive generic availability |
| ACE inhibitor/thiazide |
Established combination with simpler release requirements |
Lower formulation barrier |
| Verapamil extended-release monotherapy |
Single active with modified release |
Competes for verapamil-treated patients but lacks renin-angiotensin blockade |
The combination has a narrower market than many ACE inhibitor/amlodipine or ARB/amlodipine products. Its value lies in patients who require verapamil’s cardiac and vascular effects and need additional renin-angiotensin system inhibition.
What patent litigation and settlement agreements affect the product?
No major current litigation or settlement agreement should be assumed without a live review of PACER, FDA Paragraph IV records, ANDA litigation reports and company filings. Historical disputes, if any, would most likely have concerned formulation patents or generic certification challenges rather than active-ingredient patents.
A Paragraph IV challenge would be commercially meaningful only if an unexpired, listed patent remained relevant to the proposed dosage form. For an old combination product, the more likely pathway is an ANDA relying on expired patents or a paragraph III certification where a listed patent has not yet expired.
What are the geographic opportunities?
The product can have different commercial positions by market:
- United States: generic entry opportunity, subject to current Orange Book and reference-product status.
- European Union: national or decentralized approval strategy, with country-specific reimbursement and substitution rules.
- Canada: potential opportunity where fixed-dose combination demand supports registration.
- Latin America: lower-cost combination products may compete effectively, but local registration and manufacturing rules vary.
- Asia-Pacific: hypertension prevalence supports demand, though domestic manufacturers may create strong price competition.
Patent expiry and regulatory approval status must be assessed separately for each jurisdiction. A U.S. patent conclusion does not establish freedom to operate in Europe, China, India or Brazil.
What is the revenue exposure for the originator?
Tarka is an established product rather than a major current growth asset. Revenue exposure is therefore likely limited relative to newer branded cardiovascular products. Generic erosion, payer substitution and discontinuation risk can reduce branded sales rapidly once multiple therapeutically equivalent products are available.
For a generic entrant, revenue depends on:
- Number of approved competitors.
- Product availability by strength.
- Wholesale acquisition price.
- Pharmacy benefit manager contracting.
- Back-order frequency among competitors.
- Ability to supply all strengths.
- Whether the reference product remains commercially available.
Key Takeaways
- Trandolapril/verapamil hydrochloride is a small-molecule fixed-dose combination with expired core exclusivity.
- The main formulation challenge is combining immediate-release trandolapril with extended-release verapamil.
- A bilayer or physically segregated tablet can reduce release interference and improve low-dose content uniformity.
- Hypromellose, ethylcellulose, lactose, microcrystalline cellulose, povidone and crospovidone are commercially relevant excipient platforms.
- Generic entry risk is high, but modified-release bioequivalence and manufacturing complexity create technical barriers.
- Biosimilar risk is not applicable.
- Current Orange Book listings, reference-product status and any residual formulation patents must be confirmed before launch or licensing decisions.
- The best commercial opportunities are generic supply, modified-release excipients, low-moisture systems, direct compression and international registration.
FAQs
Is trandolapril/verapamil hydrochloride an extended-release product?
Yes. The combination uses immediate-release trandolapril and extended-release verapamil hydrochloride.
Can trandolapril and verapamil be formulated as a bilayer tablet?
Yes. A bilayer design can separate the immediate-release trandolapril phase from the sustained-release verapamil phase and improve control of dissolution.
Which excipient controls verapamil release?
The release-controlling excipient is typically a polymer matrix, such as hypromellose or ethylcellulose. Polymer grade, concentration, compression and tablet porosity also affect release.
Is there a biosimilar pathway for Tarka?
No. Tarka contains small-molecule active ingredients. Generic applicants use the ANDA pathway rather than the biosimilar pathway.
What is the largest development risk for a generic Tarka product?
The largest risk is failure to reproduce the reference product’s extended-release verapamil exposure and dissolution profile while maintaining trandolapril content uniformity.
References
-
DailyMed. (n.d.). Tarka: Trandolapril and verapamil hydrochloride extended-release tablets, prescribing information. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (1997). SUPAC-MR: Modified release solid oral dosage forms scale-up and postapproval changes: Chemistry, manufacturing, and controls; in vitro dissolution testing and in vivo bioequivalence documentation. FDA.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
